Pcv17 Association Between Exposure/Adherence to a Cardiovascular Risk Management Program and the Incidence and Mortality of Cardiovascular Events in the Caribbean Region of Colombia

Abstract

whichever was earlier. Cox regression analyses were used to examine the impact of switching to another OAC (vs. continuing apixaban) on the risk of MB-related or stroke/SE-related hospitalization during follow-up, while controlling for differences in patient characteristics. Results: Among 7,858 elderly NVAF patients who initiated treatment with apixaban included in the study, 14% (N=1,110; mean age: 78 years; 51% male) were Switchers; 86% (N=6,748; mean age: 79 years; 46% male) were Continuers. Switchers had higher unadjusted rates of MB-related (8.2% vs. 2.2%; p,0.001) and stroke/SE-related (3.2% vs. 1.4%, p,0.001) hospitalization vs. Continuers during follow-up. Cox regression models showed that apixaban Switchers vs. Continuers had a significantly greater risk of MB-related hospitalization (hazard ratio [HR]: 2.0; 95% CI: 1.5-2.6; p,0.001) during follow-up; the risk of stroke/SE hospitalization did not significantly differ (HR: 1.4, 95% CI: 0.9-2.1, p=0.15). Conclusions: In the real-world setting in the US, among elderly NVAF patients who initiated apixaban treatment, there was an association between switching to another OAC and a higher rate of MB-related hospitalization during follow-up compared to continuing the treatment.